Manufacturing of Covid-19 Vaccination doses is one of the most important issues in the world of pharmaceutical companies these days. Some of the leading companies in this field are continuously trying their best to meet the rising global demand. At this high time, Johnson and Johnson and Emergent BioSolutions Inc Monday came to a decision to terminate their agreement to make the doses of Covid-19 Vaccine.
What is Emergent saying?
According to Emergent Johnson and Johnson failed to buy the minimum quantity of COVID-19 vaccines made by the company. They added that while failing to fulfill the minimum requirements of the agreement Johnson and Johnson the American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods, has also failed to provide required forecasts for the number of vaccines it needed.
What are Johnson and Johnson saying?
On the other hand, Johnson and Johnson stated that the information provided by Emergent BioSolutions is “false and misleading”. According to them they have sufficient capacity across their global COVID-19 vaccine manufacturing network and can continue to meet their contractual obligations to supply vaccine.
Emergent’s Baltimore plant paused the manufacturing of doses last year after they got to know that ingredients from AstraZeneca’s COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J’s vaccines. The contamination resulted in the destruction of key ingredients that would have amounted to roughly 400 million doses of COVID-19 vaccines from J&J and AstraZeneca. Added to that due to safety concerns the use of the COVID-19 Vaccine produced by Johnson and Johnson has been restricted by the Food and Drug Administration of the United States in May.
Closure of the Agreement
At first, J&J provided formal notice of termination and breach to Emergen. Eventually, Emergent BioSolutions said in a securities filing that it had sent a notice of material breach of the agreement to J&J.
